Zai Lab Limited announced that the 2023 National Reimbursement Drug List (NRDL) released by China?s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: VYVGART® (efgartigimod alfa injection) is included for the first time in the NRDL for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive; NUZYRA® (omadacycline) is included for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI); and ZEJULA® (niraparib) is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.03 USD | -0.31% | +3.60% | -31.05% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.05% | 1.89B | |
+0.99% | 91.72B | |
0.00% | 39.44B | |
-10.01% | 34.47B | |
+64.64% | 26.7B | |
-17.33% | 15.13B | |
-6.25% | 13.27B | |
-10.69% | 11.74B | |
-47.78% | 10.54B | |
+8.09% | 9.41B |
- Stock Market
- Equities
- ZLAB Stock
- News Zai Lab Limited
- Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List